CXCR4 and cancer: Although some compounds have been reported to prevent IA, such as the CXCR4 antagonist AMD3100, which targets SDF1/CXCR4 signaling [61], evidence on the efficacy of strategies to act on IA and their value in cancer therapy are far from conclusive.